Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers

被引:51
作者
Dutu, T
Michiels, S
Fouret, P
Penault-Llorca, F
Validire, P
Benhamou, S
Taranchon, E
Morat, L
Grunenwald, D
Le Chevalier, T
Sabatier, L
Soria, JC
机构
[1] Inst Gustave Roussy, Dept Med, F-94805 Villejuif, France
[2] Inst Gustave Roussy, Dept Pathol, F-94805 Villejuif, France
[3] Inst Gustave Roussy, Dept Biostat, F-94805 Villejuif, France
[4] Inst Gustave Roussy, CNRS, UPR 2169, F-94805 Villejuif, France
[5] Inst Gustave Roussy, Translat Res Unit, F-94805 Villejuif, France
[6] Ctr Jean Perrin, Dept Pathol, Clermont Ferrand, France
[7] Inst Mutualiste Montsouris, Dept Pathol, Paris, France
[8] Inst Mutualiste Montsouris, Dept Thorac, Paris, France
[9] CEA, Lab Radiobiol & Oncol, Fontenay Aux Roses, France
关键词
EGFR; immunohistochemistry; lung adenocarcinoma; never-smokers; pAKT;
D O I
10.1093/annonc/mdi408
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Non-small-cell lung cancer arising in never-smokers is usually of adenocarcinoma subtype. The oncogenic pathway of such tumors is poorly understood. To better define the biological characteristics of these tumors, we have compared the expression of a panel of epidermal growth factor receptor (EGFR)-related biomarkers in lung adenocarcinomas from smokers versus those in never-smokers. Patients and methods: Using immunohistochemical analysis, we retrospectively analyzed EGFR, pAKT, PTEN, Ki-67, p27 and hTERT expression in specimens from 190 patients with completely resected lung adenocarcinomas (43 never-smokers and 147 smokers). These analyses were performed on tissue microarrays. Results: EGFR expression was higher in tumors from smokers (P < 0.01), while pAKT was overexpressed mainly in tumors from never-smokers (P = 0.01). As expected, the tumors from smokers presented a higher expression of Ki-67 and a more frequent loss of expression of p27 (P < 0.01). In a multivariate model, two biological factors (p27 and Ki-67) and two clinical factors (age and sex) showed independent significant correlation with never-smoking status. Conclusions: Lung adenocarcinomas in never-smokers have a very distinct immunohistochemical expression profile of EGFR-related biomarkers as compared with lung adenocarcinomas in smokers. High levels of EGFR and Ki-67 are observed in smokers, while never-smokers are characterized by high levels of pAKT and p27.
引用
收藏
页码:1906 / 1914
页数:9
相关论文
共 52 条
[1]   High telomerase activity in primary lung cancers: Association with increased cell proliferation rates and advanced pathologic stage [J].
Albanell, J ;
Lonardo, F ;
Rusch, V ;
Engelhardt, M ;
Langenfeld, J ;
Han, W ;
Klimstra, D ;
Venkatraman, E ;
Moore, MAS ;
Dmitrovsky, E .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (21) :1609-1615
[2]   Epidemiology of lung cancer [J].
Alberg, AJ ;
Samet, JM .
CHEST, 2003, 123 (01) :21S-49S
[3]  
Brognard J, 2001, CANCER RES, V61, P3986
[4]   Gefitinib in pretreated non-small-cell lung cancer (NSCLC):: Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC [J].
Cappuzzo, F ;
Gregorc, V ;
Rossi, E ;
Cancellieri, A ;
Magrini, E ;
Paties, CT ;
Ceresoli, G ;
Lombardo, L ;
Bartolini, S ;
Calandri, C ;
De Rosa, M ;
Villa, E ;
Crinò, L .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2658-2663
[5]   Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].
Cappuzzo, F ;
Hirsch, FR ;
Rossi, E ;
Bartolini, S ;
Ceresoli, GL ;
Bemis, L ;
Haney, J ;
Witta, S ;
Danenberg, K ;
Domenichini, I ;
Ludovini, V ;
Magrini, E ;
Gregorc, V ;
Doglioni, C ;
Sidoni, A ;
Tonato, M ;
Franklin, WA ;
Crino, L ;
Bunn, PA ;
Varella-Garcia, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655
[6]   Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer [J].
Cappuzzo, F ;
Magrini, E ;
Ceresoli, GL ;
Bartolini, S ;
Rossi, E ;
Ludovini, V ;
Gregorc, V ;
Ligorio, C ;
Cancellieri, A ;
Damiani, S ;
Spreafico, A ;
Paties, CT ;
Lombardo, L ;
Calandri, C ;
Bellezza, G ;
Tonato, M ;
Crinò, L .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) :1133-1141
[7]   A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers [J].
D'Amico, TA ;
Massey, M ;
Herndon, JE ;
Moore, MB ;
Harpole, DH .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 117 (04) :736-742
[8]   The multiple roles of PTEN in tumor suppression [J].
Di Cristofano, A ;
Pandolfi, PP .
CELL, 2000, 100 (04) :387-390
[9]   Epidermal growth factor receptor family in lung cancer and premalignancy [J].
Franklin, WA ;
Veve, R ;
Hirsch, FR ;
Helfrich, BA ;
Bunn, PA .
SEMINARS IN ONCOLOGY, 2002, 29 (01) :3-14
[10]   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].
Fukuoka, M ;
Yano, S ;
Giaccone, G ;
Tamura, T ;
Nakagawa, K ;
Douillard, JY ;
Nishiwaki, Y ;
Vansteenkiste, J ;
Kudoh, S ;
Rischin, D ;
Eek, R ;
Horai, T ;
Noda, K ;
Takata, I ;
Smit, E ;
Averbuch, S ;
Macleod, A ;
Feyereislova, A ;
Dong, RP ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246